• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 441651 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413926567 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413926567 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Pharmacyclics on 2.2x Above-Average Volume (PCYC)

Published on Wed, 02/13/2013 - 14:11
By Mallory Stone

Pharmacyclics shares are trading on heavy volume today, having risen 7.5% to $75.66. About 956,000 shares have been traded today, as compared to the 30-day average volume of 434,000 shares. Unusually high volume can signify a potential turning point or validate a breakout.

In the past 52 weeks, Pharmacyclics share prices have been bracketed by a low of $22.70 and a high of $76.00 and are now at $75.66, 233% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.6%.

Potential upside of 6.7% exists for Pharmacyclics, based on a current level of $75.66 and analysts' average consensus price target of $80.75. The stock should discover initial support at its 50-day moving average (MA) of $64.13 and subsequent support at its 200-day MA of $54.93.

Pharmacyclics, Inc. is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. The Company's products are patented agents derived from its technology platform for designing and synthesizing energy-potentiating drugs.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Rentrak Looks to Continue to Trade Above...

Rentrak (NASDAQ:RENT) traded at a new 52-week high today of $76.50. So far today appro ...

Watch for Continued Gains in Shares of O...

Shares of O'Reilly Automotive (NASDAQ:ORLY) traded today at $158.93, breaking its 52-we ...

Netease.com: The Winning Streak Continue...

Netease.com (NASDAQ:NTES) traded at a new 52-week high today of $94.97. This new high ...

Watch for Continued Gains in Shares of N...

Shares of Nautilus (NYSE:NLS) traded at a new 52-week high today of $13.41. This new h ...

Watch for Continued Gains in Shares of M...

Micron Technology (NASDAQ:MU) traded at a new 52-week high today of $30.93. This new h ...

Monster Worldwide Looks to Continue to T...

Monster Worldwide (NASDAQ:MNST) traded today at a new 52-week high of $99.05. So far t ...

Watch for Continued Gains in Shares of L...

Landstar System (NASDAQ:LSTR) traded at a new 52-week high today of $74.02. So far tod ...

Shares of Kilroy Realty Rise to a New 52...

Shares of Kilroy Realty (NYSE:KRC) traded at a new 52-week high today of $64.36. This ...